Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Nivolumab, and Blinatumomab for Richter Transformation
NCT03121534Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in Richter's syndrome (RS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 2 months. Started Jun 2017; status: terminated.
02
Drugs
blinatumomab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT03121534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121534.